CRISPR THERAPEUTICS AG Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount
CRISPR THERAPEUTICS AG (CRSP) had Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount of $72.00 million as of 2023-12-31, per its 10-K filed 2024-02-21.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions · last filed 2024-02-21
- 2023-12-31: Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $72.00M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount |
|---|---|
| 2023-12-31 | $72.00M 10-K · filed 2024-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |